


Product Name : Umbralisib
Synonyms : RP 5264; TGR1202; TGR-1202
Cat No. : M12154
CAS Number : 1532533-67-7
Molecular Formula : C₃₁H₂₄F₃N₅O₃
Formula Weight : 571.55



Chemical Name : 4H-1-Benzopyran-4-one, 2-[(1S)-1-[4-amino-3-[3-fluoro-4-(1-methylethoxy)phenyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)-

Description : Umbralisib (RP5264, TGR1202, TGR-1202) is a potent, selective, orally available PI3Kδ inhibitor with IC₅₀ of 22 nM, 50-fold selectivity over PI3Kα/β and >10,000 fold over PI3Kγ; enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest, demonstrates highly synergistic effect with the proteasome inhibitor carfilzomib in lymphoma, leukemia, and myeloma cell lines and primary lymphoma and leukemia cells; synergistically disrupts the 4E-BP1-eIF4F-c-Myc axis with carfilzomib, also potently inhibits 60% of the activity of CK1ε at 1 μM. Blood Cancer Phase 3 Clinical

Pathway : PI3K/Akt/mTOR signaling

Target : PI3K

Receptor : PI3Kδ

Solubility : 10 mM in DMSO

SMILES : O=C1C(C2=CC=CC(F)=C2)=C([C@@H](N3N=C(C4=CC=C(OC(C)C)C(F)=C4)C5=C(N)N=CN=C53)C)OC6=CC=C(F)C=C16

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1. Locatelli SL, et al. Leukemia. 2016 Dec;30(12):2402-2405. | 2. Deng C, et al. Blood. 2017 Jan 5;129(1):88-99. | 3. Burris HA 3rd, et al. Lancet Oncol. 2018 Feb 20. pii: S1470-2045(18)30082-2.